ENLIVEX THERAPEUTI is trading at 3649.00 as of the 18th of September 2021, a -1.38 percent down since the beginning of the trading day. The stock's open price was 3700.0. Equity ratings for ENLIVEX THERAPEUTI are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 20th of July 2021 and ending today, the 18th of September 2021. Click here to learn more.
Check how we calculate scores


Enlivex Therapeutics Ltd. operates as a clinical stage immunotherapy company. Enlivex Therapeutics Ltd. was incorporated in 2005 and is headquartered in Nes Ziona, Israel. ENLIVEX THERAPEUTI operates under Biotechnology classification in Israel and is traded on Tel Aviv Stock Exchange. It employs 50 people. more on ENLIVEX THERAPEUTI
ENLIVEX THERAPEUTI is not yet fully synchronised with the market data
ENLIVEX THERAPEUTI is way too risky over 90 days horizon
ENLIVEX THERAPEUTI appears to be risky and price may revert if volatility continues
Net Loss for the year was (14.3 M).
ENLIVEX THERAPEUTI has accumulated about 90.6 M in cash with (14.86 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.95.
Roughly 22.0% of the company shares are held by company insiders
CEODror Mevorach  (View All)
Macroaxis Advice
Unlike general analyst consensus, Macroaxis buy hold or sell recommendation is provided in the context of your current investment horizon and risk tolerance. The advice algorithm takes into account all of ENLIVEX THERAPEUTI's available fundamental, technical, and predictive indicators. Your current horizon is 90 days - details
Not RatedOvervalued
ENLIVEX THERAPEUTI (ENLV) is traded on Tel Aviv Stock Exchange in Israel and employs 50 people. The company currently falls under 'Large-Cap' category with current market capitalization of 78.07 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate ENLIVEX THERAPEUTI's market, we take the total number of its shares issued and multiply it by ENLIVEX THERAPEUTI's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities. ENLIVEX THERAPEUTI operates under Healthcare sector and is part of Biotechnology industry. The entity has 18.31 M outstanding shares. ENLIVEX THERAPEUTI has accumulated about 90.6 M in cash with (14.86 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.95.
Check ENLIVEX THERAPEUTI Probability Of Bankruptcy

ENLIVEX Stock Price Odds Analysis

What are ENLIVEX THERAPEUTI's target price odds to finish over the current price? Depending on a normal probability distribution, the odds of ENLIVEX THERAPEUTI jumping above the current price in 90 days from now is about 9.49%. The ENLIVEX THERAPEUTI probability density function shows the probability of ENLIVEX THERAPEUTI stock to fall within a particular range of prices over 90 days. Assuming the 90 days trading horizon ENLIVEX THERAPEUTI has a beta of 0.0321 suggesting as returns on the market go up, ENLIVEX THERAPEUTI average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding ENLIVEX THERAPEUTI will be expected to be much smaller as well. Additionally, the company has an alpha of 0.0245, implying that it can generate a 0.0245 percent excess return over DOW after adjusting for the inherited market risk (beta).
 Odds Down 3649.0HorizonTargetOdds Up 3649.0 
90.46%90 days
Based on a normal probability distribution, the odds of ENLIVEX THERAPEUTI to move above the current price in 90 days from now is about 9.49 (This ENLIVEX THERAPEUTI probability density function shows the probability of ENLIVEX Stock to fall within a particular range of prices over 90 days) .


Investors will always prefer to have the highest possible return on investment while minimizing volatility. ENLIVEX THERAPEUTI market risk premium is the additional return an investor will receive from holding ENLIVEX THERAPEUTI long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in ENLIVEX THERAPEUTI. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Although ENLIVEX THERAPEUTI's alpha and beta are two of the key measurements used to evaluate ENLIVEX THERAPEUTI's performance over the market, the standard measures of volatility play an important role as well.

ENLIVEX Stock Against Markets

Picking the right benchmark for ENLIVEX THERAPEUTI stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in ENLIVEX THERAPEUTI stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for ENLIVEX THERAPEUTI is critical whether you are bullish or bearish towards ENLIVEX THERAPEUTI at a given time.

View Currently Related Equities

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with ENLIVEX THERAPEUTI stock to make a market-neutral strategy. Peer analysis of ENLIVEX THERAPEUTI could also be used in its relative valuation, which is a method of valuing ENLIVEX THERAPEUTI by comparing valuation metrics with similar companies.

ENLIVEX THERAPEUTI Corporate Executives

Elected by the shareholders, the ENLIVEX THERAPEUTI's board of directors comprises two types of representatives: ENLIVEX THERAPEUTI inside directors who are chosen from within the company, and outside directors, selected externally and held independent of ENLIVEX. The board's role is to monitor ENLIVEX THERAPEUTI's management team and ensure that shareholders' interests are well served. ENLIVEX THERAPEUTI's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, ENLIVEX THERAPEUTI's outside directors are responsible for providing unbiased perspectives on the board's policies.
Shachar Shlosberger - Chief Financial OfficerProfile
Continue to Investing Opportunities. Note that the ENLIVEX THERAPEUTI information on this page should be used as a complementary analysis to other ENLIVEX THERAPEUTI's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.

Other Tools for ENLIVEX Stock

When running ENLIVEX THERAPEUTI price analysis, check to measure ENLIVEX THERAPEUTI's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ENLIVEX THERAPEUTI is operating at the current time. Most of ENLIVEX THERAPEUTI's value examination focuses on studying past and present price action to predict the probability of ENLIVEX THERAPEUTI's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move ENLIVEX THERAPEUTI's price. Additionally, you may evaluate how the addition of ENLIVEX THERAPEUTI to your portfolios can decrease your overall portfolio volatility.
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Fundamental Analysis
View fundamental data based on most recent published financial statements
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Bond Directory
Find actively traded corporate debentures issued by US companies
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
CEO Directory
Screen CEOs from public companies around the world
Content Syndication
Quickly integrate customizable finance content to your own investment portal
ETF Directory
Find actively traded Exchange Traded Funds (ETF) from around the world
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device